Mario Germano Giuliani Sells 154,986 Shares of Royalty Pharma plc (NASDAQ:RPRX) Stock

Royalty Pharma plc (NASDAQ:RPRXGet Rating) Director Mario Germano Giuliani sold 154,986 shares of the stock in a transaction dated Friday, September 16th. The stock was sold at an average price of $41.72, for a total transaction of $6,466,015.92. Following the transaction, the director now owns 22,890,000 shares of the company’s stock, valued at approximately $954,970,800. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Mario Germano Giuliani also recently made the following trade(s):

  • On Monday, September 19th, Mario Germano Giuliani sold 232,185 shares of Royalty Pharma stock. The stock was sold at an average price of $41.50, for a total transaction of $9,635,677.50.
  • On Wednesday, September 7th, Mario Germano Giuliani sold 261,881 shares of Royalty Pharma stock. The stock was sold at an average price of $42.66, for a total transaction of $11,171,843.46.
  • On Thursday, August 25th, Mario Germano Giuliani sold 500 shares of Royalty Pharma stock. The stock was sold at an average price of $44.00, for a total transaction of $22,000.00.

Royalty Pharma Trading Down 0.8 %

Shares of RPRX opened at $40.70 on Thursday. The firm’s 50 day simple moving average is $43.00 and its 200 day simple moving average is $41.49. The company has a market capitalization of $24.71 billion, a P/E ratio of 52.86, a P/E/G ratio of 1.11 and a beta of 0.30. The company has a debt-to-equity ratio of 0.68, a current ratio of 19.22 and a quick ratio of 19.22. Royalty Pharma plc has a 1-year low of $34.86 and a 1-year high of $44.75.

Royalty Pharma Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 15th. Shareholders of record on Friday, August 19th were paid a dividend of $0.19 per share. This represents a $0.76 annualized dividend and a dividend yield of 1.87%. The ex-dividend date of this dividend was Thursday, August 18th. Royalty Pharma’s dividend payout ratio (DPR) is presently 98.70%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on RPRX. Citigroup increased their price target on shares of Royalty Pharma from $50.00 to $60.00 in a report on Thursday, July 28th. Tigress Financial increased their price target on shares of Royalty Pharma from $52.00 to $57.00 and gave the stock a “buy” rating in a report on Thursday, July 14th. UBS Group began coverage on shares of Royalty Pharma in a report on Monday, June 13th. They issued a “buy” rating and a $47.00 price target on the stock. Finally, Morgan Stanley increased their price target on shares of Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a report on Monday, August 8th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $53.43.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Signaturefd LLC raised its stake in shares of Royalty Pharma by 53.9% during the first quarter. Signaturefd LLC now owns 688 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 241 shares in the last quarter. Captrust Financial Advisors raised its stake in shares of Royalty Pharma by 210.8% during the second quarter. Captrust Financial Advisors now owns 805 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 546 shares in the last quarter. Newfound Research LLC purchased a new position in shares of Royalty Pharma during the second quarter worth approximately $50,000. PNC Financial Services Group Inc. raised its stake in shares of Royalty Pharma by 54.5% during the first quarter. PNC Financial Services Group Inc. now owns 3,423 shares of the biopharmaceutical company’s stock worth $133,000 after acquiring an additional 1,208 shares in the last quarter. Finally, Gladius Capital Management LP purchased a new position in shares of Royalty Pharma during the first quarter worth approximately $143,000. 54.94% of the stock is owned by hedge funds and other institutional investors.

Royalty Pharma Company Profile

(Get Rating)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

See Also

Insider Buying and Selling by Quarter for Royalty Pharma (NASDAQ:RPRX)

Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.